An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

THE setting up of a revolving fund to grow the pharmaceutical industry is facing further delays as resources will only be ...

Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...

Piramal Pharma reported a 12.54% increase in revenue for Q3 2025, despite a significant 63.6% decrease in profit, which stood ...

Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00.

In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

The company will report earnings before the open on Jan. 29 Israel-based pharmaceutical giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is preparing for its latest quarterly earnings report, due ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

Today, companies like TVS Motor Company, Hindustan Zinc, Hyundai Motor India, GMR Airports, Bajaj Auto, Cipla, Piramal Pharma ...

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...